Search by year - Any -2024202320222021202020192018201720162015 4 April 2023 Biocartis and APIS Assay Technologies Sign Collaboration to Develop and Commercialise a Breast Cancer Subtyping Test on the Idylla Platform Non-regulated information 2 March 2023 Biocartis announces the US FDA 510(k) clearance for the Idylla MSI Test Non-regulated information 9 February 2023 Biocartis announces the launch of the first assay developed with the new Idylla FLEX technology Non-regulated information 8 November 2022 New Idylla EGFR Study Shows Reduction of Time-to-Treatment by 48% for Lung Cancer Patients Non-regulated information 31 October 2022 Biocartis Announces Nine Idylla Studies to be Published at Upcoming AMP 2022 Annual Meeting Non-regulated information 10 October 2022 Biocartis Initiates Commercialization in Europe of HepatoPredict (CE-IVD) Test for Liver Cancer Patients Non-regulated information 1 September 2022 Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma Patients Non-regulated information 24 August 2022 Biocartis Obtains ISO 27001 Certification for Information Security Management Non-regulated information 22 June 2022 Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso® Non-regulated information 20 June 2022 Biocartis Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer Non-regulated information Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »